NCT00247572View on ClinicalTrials.gov

Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2005

Study Completion Date

November 30, 2005

Conditions
Attention Deficit Disorder With HyperactivityAmphetamine-Related DisordersSubstance-Related Disorders
Interventions
DRUG

NRP104

Trial Locations (1)

21224

Johns Hopkins Bayview Medical Center, Clinical Studies Program, Baltimore

Sponsors
All Listed Sponsors
lead

New River Pharmaceuticals

INDUSTRY

NCT00247572 - Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories | Biotech Hunter | Biotech Hunter